Clinical Trial
Accepted on 09 Feb 2026
Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma
in Cancer Immunity and Immunotherapy
Clinical Trial
Accepted on 09 Feb 2026
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 09 Feb 2026
in Public Health Education and Promotion
Original Research
Accepted on 09 Feb 2026
in AI in Food, Agriculture and Water
Original Research
Accepted on 09 Feb 2026
in Marine Affairs and Policy
Original Research
Accepted on 09 Feb 2026
in Public Health Education and Promotion
Original Research
Accepted on 09 Feb 2026
in Pediatric Dentistry
Original Research
Accepted on 09 Feb 2026
in Higher Education
Original Research
Accepted on 09 Feb 2026
in Technology and Innovation in Auditory Implants and Hearing Aids
Original Research
Accepted on 09 Feb 2026
in Gastrointestinal Cancers: Colorectal Cancer
Systematic Review
Accepted on 09 Feb 2026
in Heart Failure and Transplantation
Case Report
Accepted on 09 Feb 2026
in Coronary Artery Disease
Original Research
Accepted on 09 Feb 2026
in Higher Education
Original Research
Accepted on 09 Feb 2026
in Diabetes Therapies
Original Research
Accepted on 09 Feb 2026
in Infectious Diseases: Pathogenesis and Therapy
Original Research
Accepted on 09 Feb 2026
in Ophthalmology
Systematic Review
Accepted on 09 Feb 2026
in Marine Fisheries, Aquaculture and Living Resources